Loading...
•
Sep 30, 2023
Bicycle Q3 2023 Earnings Report
Reported financial results for the third quarter ended September 30, 2023, and provided recent corporate updates.
Key Takeaways
Bicycle Therapeutics reported their Q3 2023 financial results, highlighting alignment with the FDA on an expedited development plan for BT8009 and its selection for the FDA's CMC Development and Readiness Pilot Program. They also announced an upcoming R&D Day on December 14 to provide clinical updates for BT8009, BT5528 and BT7480.
Aligned with the FDA on expedited development and design of Phase 2/3 registrational trial for BT8009 in metastatic bladder cancer, to be initiated in 1Q 2024.
BT8009 was selected for new FDA Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) Program.
Cash and cash equivalents of $572.1 million as of September 30, 2023, including approximately $215.1 million in net proceeds from July 2023 public offering
Planned R&D Day on December 14, 2023, to provide clinical updates for BT8009, BT5528 and BT7480.
Forward Guidance
Bicycle Therapeutics anticipates advancement of its product candidates, including BT8009, BT5528 and BT7480, progression of its clinical trials, including the timing of initiation and design of the Duravelo-2 Phase 2/3 clinical trial and potential accelerated approval of BT8009.
Positive Outlook
- Advancement of its product candidates, including BT8009, BT5528 and BT7480
- Progression of Bicycle’s clinical trials
- Timing of initiation and design of the Duravelo-2 Phase 2/3 clinical trial
- Potential accelerated approval of BT8009
- Potential earlier patient access to BT8009
Challenges Ahead
- Uncertainties inherent in the initiation, progress and completion of clinical trials and clinical development of Bicycle’s product candidates
- The risk that Bicycle may not realize the intended benefits of its technology or strategic collaborations
- Availability and timing of results from clinical trials
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...